Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Precision Telemed vs Embody

Two GLP-1 deals, scored on the same six factors. Precision Telemed lands a Value Score of 89, Embody a 85. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Precision Telemed

#10 · Grade A · Great Deal

Est. first month

$149/mo

Save ~89% vs brand-name
Get this deal Full Precision Telemed review →
VS

Embody

#33 · Grade A- · Great Deal

Est. first month

From $79/mo (all doses, compounded)

Save ~94% vs brand-name
Get this deal Full Embody review →

The verdict

Better value: Precision Telemed

Precision Telemed takes it on Value Score, 89 to 85 an est. $149/mo first month, with no teaser step-up baked in. Embody isn't out of it: Shoppers who want low flat-rate compounded GLP-1 pricing at every dose.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealPrecision TelemedEmbody
Value Score89 (A)85 (A-)
Est. first month$149/moFrom $79/mo (all doses, compounded)
Save vs brand-name~89%~94%
Semaglutide$149/moFrom $79/mo (all doses, compounded)
Tirzepatide$199/moFrom $129/mo (all doses, compounded)
Both moleculesYesYes
PricingFlat — no step-upWatch
CoverageAll 50 statesAll 50 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

88
Lowest Real Price
90
Precision Telemed: 88. Embody: 90.
86
No Teaser-Rate Bait
80
Precision Telemed: 86. Embody: 80.
98
Nationwide Availability
96
Precision Telemed: 98. Embody: 96.
92
Both Molecules
98
Precision Telemed: 92. Embody: 98.
84
Easy Cancellation
62
Precision Telemed: 84. Embody: 62.
82
Reputation
68
Precision Telemed: 82. Embody: 68.

Precision Telemed

A LegitScript-certified, all-50-state program with an honest $149 / $199 flat price on both molecules.

Why it's a deal

  • LegitScript-certified and available in all 50 states
  • Flat $149 semaglutide / $199 tirzepatide — no step-up
  • Both molecules priced up front

The fine print

  • Not the rock-bottom sticker — sub-$100 sema tiers exist
  • No brand-name or oral option

Embody

Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.

Why it's a deal

  • Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
  • Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
  • Available in all 50 states with no insurance friction
  • 24/7 unlimited clinician messaging and dose-adjustment support included
  • Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine

The fine print

  • The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
  • Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
  • Pharmacy partners not publicly named — compounding source transparency is limited
  • Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Get the Precision Telemed deal Get the Embody deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Precision Telemed is ranked on the Precision Telemed alternatives board, and the same list for the other side is on alternatives to Embody.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.